Mission Street has appointed investor Tim Funnell to its advisory board to support expansion across core science markets in the UK.
Funnell (pictured) is a partner with Monograph Capital, a venture capital fund investing across the life sciences sector. He also serves as chief executive of Ascend, a gene therapy manufacturing business, and was a co-founder of MiroBio, which was recently acquired by pharma giant Gilead for $405m (£395m).
Funnell’s appointment comes at a time when UK life science start-ups are being constrained by the lack of labs to support growth and scale-up. Mission Street aims to correct this “market failure” through the delivery of real estate that responds to changing occupier trends and supports the full lifecycle of companies.
